Jazz Pharmaceuticals PLC $JAZZ Holdings Raised by Allianz Asset Management GmbH

Allianz Asset Management GmbH grew its position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 453.9% in the second quarter, Holdings Channel.com reports. The fund owned 325,403 shares of the specialty pharmaceutical company’s stock after buying an additional 266,658 shares during the period. Allianz Asset Management GmbH’s holdings in Jazz Pharmaceuticals were worth $34,532,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in the company. Dimensional Fund Advisors LP increased its holdings in shares of Jazz Pharmaceuticals by 14.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,328,430 shares of the specialty pharmaceutical company’s stock valued at $289,066,000 after acquiring an additional 293,360 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Jazz Pharmaceuticals by 4.7% in the 1st quarter. JPMorgan Chase & Co. now owns 1,662,042 shares of the specialty pharmaceutical company’s stock valued at $206,343,000 after acquiring an additional 74,501 shares during the last quarter. Fuller & Thaler Asset Management Inc. increased its holdings in shares of Jazz Pharmaceuticals by 41.7% in the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 1,331,011 shares of the specialty pharmaceutical company’s stock valued at $165,245,000 after acquiring an additional 391,660 shares during the last quarter. Swedbank AB increased its holdings in shares of Jazz Pharmaceuticals by 10.0% in the 1st quarter. Swedbank AB now owns 1,102,143 shares of the specialty pharmaceutical company’s stock valued at $136,831,000 after acquiring an additional 100,211 shares during the last quarter. Finally, Perpetual Ltd increased its holdings in shares of Jazz Pharmaceuticals by 60.2% in the 1st quarter. Perpetual Ltd now owns 952,172 shares of the specialty pharmaceutical company’s stock valued at $118,212,000 after acquiring an additional 357,784 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors.

Insider Activity at Jazz Pharmaceuticals

In other news, Director Bruce C. Cozadd sold 3,500 shares of the company’s stock in a transaction on Friday, October 3rd. The stock was sold at an average price of $140.00, for a total transaction of $490,000.00. Following the completion of the sale, the director directly owned 408,826 shares of the company’s stock, valued at $57,235,640. This represents a 0.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders sold 11,500 shares of company stock worth $1,525,280 over the last three months. Corporate insiders own 4.30% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on JAZZ. Weiss Ratings reiterated a “sell (d)” rating on shares of Jazz Pharmaceuticals in a report on Wednesday, October 8th. Deutsche Bank Aktiengesellschaft started coverage on Jazz Pharmaceuticals in a research report on Tuesday, July 15th. They set a “buy” rating and a $152.00 price objective for the company. Royal Bank Of Canada boosted their price objective on Jazz Pharmaceuticals from $145.00 to $151.00 and gave the company an “outperform” rating in a research report on Thursday, August 28th. Zacks Research upgraded Jazz Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Friday, August 15th. Finally, The Goldman Sachs Group boosted their price objective on Jazz Pharmaceuticals from $162.00 to $185.00 and gave the company a “buy” rating in a research report on Friday, August 29th. Fourteen research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $178.93.

Jazz Pharmaceuticals Trading Up 1.3%

Shares of JAZZ stock opened at $136.06 on Friday. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.37 and a current ratio of 1.62. Jazz Pharmaceuticals PLC has a 1 year low of $95.49 and a 1 year high of $148.06. The stock has a fifty day moving average of $128.20 and a two-hundred day moving average of $116.00. The firm has a market capitalization of $8.25 billion, a PE ratio of -20.22, a price-to-earnings-growth ratio of 8.35 and a beta of 0.28.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($5.61) by ($2.64). The business had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.05 billion. Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The company’s revenue was up 2.1% compared to the same quarter last year. During the same quarter last year, the firm posted $5.30 EPS. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. As a group, research analysts expect that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.